EUCTR2008-006424-54-FR进行中（未招募）1 期
An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with Inhibitors
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Informed consent obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the patient.)
- •2. Male Haemophilia A or B patients with inhibitors
- •3. Aged between 12 and 65 years, both inclusive
- •4. Willing to undergo a bleeding preventive regimen of 3 months duration and a total trial length of approximately 8 months
- •5. Historical or ongoing high titer inhibitor (= 5 BU) based on either medical records,
- •laboratory report reviews, patient and/or care provider interviews
- •6. At least 2 bleeding episodes requiring bypassing haemostatic-drug-based treatment within the last month or 12 bleeding episodes within the last 6 months prior to Observation period
- •7. Body weight between 30 and 100 kg (both inclusive)
- •8. Patient has adequate venous access at the Screening Visit
- •9. Patient or caregiver is capable of assessing a bleed, capable of home treatment of bleeding episodes and otherwise follow the trial protocol
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Body Mass Index (BMI)>30 kg/m²
- •2. Immune tolerance induction therapy within the last 1 month prior to entering observation
- •phase period
- •3. Known active pseudo tumours
- •4. Platelet count < 50,000 platelets/µL (based on local laboratory value at Screening Visit)
- •5. Congenital or acquired coagulation disorders other than haemophilia A or B
- •6. Surgery within one month prior to the observation period. Catheter, stents and dental extractions do not count as surgeries, i.e. they will not exclude the patient. Port insertion is classified as surgery.
- •7. Scheduled major and/or orthopaedic surgery, during the trial period until Follow up visit. Catheter, stents and dental extractions do not count as surgeries and will not exclude the patient. Port insertion is classified as surgery.
- •8. Advanced atherosclerotic disease (i.e. known history of ischemic heart disease, or
- •ischemic stroke)
- •9. Any clinical signs or known history of thromboembolic events incl. known deep vein
- •thrombosis (DVT)
- •10. Known or clinically suspected allergy to rFVIIa (NovoSeven®/NovoSeven
- •RT®/Niastase®)
- •11. PT prolongation (30% above normal limits, or >5 seconds compared to control or INR >1.7 as defined by local laboratory ranges at screening visit)
- •12. Severe liver disease (ALAT > 4 times of the upper limit of normal reference range) (as defined by local laboratory ranges) within a year of enrolment or at the screening
- •13. Clinical signs of renal dysfunction (dialysis) and/or creatinine levels = 20% above upper normal limit (according to local laboratory range at the screening visit)
- •14. Dosing of any investigational drug within the last 30 days prior to the present trial
- •15. Any disease or condition which, according to the investigator’s judgement, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome
- •16. HIV positive patients; who either have low CD4+ lymphocyte count (= 200/µl based on medical records within 6 months or lab screening at screening visit), or who are HCV-PCR positive (based on medical records), or who both have low CD4+ lymphocyte count (= 200/µl) and are HCV-PCR positive. If HCV-PCR testing is not locally available, a HIV positive patient who is HCV antibody positive cannot be included.
- •17. Need to use other PEGylated pharmaceutical drug during the trial period.
- •18. Mental incapacity, unwillingness or a language barrier precluding adequate
- •understanding and cooperation
研究者
相似试验
进行中（未招募）
不适用
An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with InhibitorsHaemophilia A (Factor VIII) or B with InhibitorsMedDRA version: 9.1Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)MedDRA version: 9.1Level: LLTClassification code 10060612Term: Hemophilia AEUCTR2008-006424-54-SEovo Nordisk A/S24
进行中（未招募）
不适用
An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with InhibitorsHaemophilia A (Factor VIII) or B with InhibitorsMedDRA version: 9.1Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)MedDRA version: 9.1Level: LLTClassification code 10060612Term: Hemophilia AEUCTR2008-006424-54-GBovo Nordisk A/S24
进行中（未招募）
不适用
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTEEUCTR2006-002037-20-HUTeva Pharmaceutical Industries, Ltd.980
进行中（未招募）
1 期
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) Estudio multinacional, multicéntrico, randomizado, doble ciego, en grupos paralelos, para comparar la eficacia, la tolerabilidad y seguridad del Acetato de Glatiramero inyectable 40 mg/ml frente a Acetato de Glatiramero inyectable 20 mg/ml una vez al día en inyección subcutánea en pacientes con Esclerosis Múltiple Remitente Recurrente (EM-RR) - FORTERelapsing-remitting Multiple Sclerosis (RR MS)MedDRA version: 8.1 Level: PT Classification code 10028245EUCTR2006-002037-20-ESTeva Pharmaceutical Industries, Ltd.980
进行中（未招募）
不适用
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTERelapsing-remitting Multiple Sclerosis (RR MS)MedDRA version: 8.1Level: PTClassification code 10028245EUCTR2006-002037-20-DETeva Pharmaceutical Industries, Ltd.980